Search hospitals > Minnesota > Burnsville
Minnesota Oncology - Burnsville
Claim this profileBurnsville, Minnesota 55337
Global Leader in Breast Cancer
Global Leader in Cancer
Conducts research for Lung Cancer
Conducts research for Breast cancer
Conducts research for Non-Small Cell Lung Cancer
130 reported clinical trials
10 medical researchers
Summary
Minnesota Oncology - Burnsville is a medical facility located in Burnsville, Minnesota. This center is recognized for care of Breast Cancer, Cancer, Lung Cancer, Breast cancer, Non-Small Cell Lung Cancer and other specialties. Minnesota Oncology - Burnsville is involved with conducting 130 clinical trials across 281 conditions. There are 10 research doctors associated with this hospital, such as David M. King, Daniel M. Anderson, Yan Ji, and Pamala A. Pawloski.Area of expertise
1Breast Cancer
Global LeaderHER2 positive
HER2 negative
ER positive
2Cancer
Global LeaderStage IV
Stage III
Stage II
Top PIs
David M. KingPark Nicollet Clinic - Saint Louis Park8 years of reported clinical research
Expert in Lung Cancer
Expert in Breast Cancer
104 reported clinical trials
167 drugs studied
Daniel M. AndersonAbbott-Northwestern Hospital6 years of reported clinical research
Expert in Cancer
Expert in Lung Cancer
61 reported clinical trials
110 drugs studied
Yan JiRegions Hospital2 years of reported clinical research
Studies Breast Cancer
Studies Cancer
32 reported clinical trials
78 drugs studied
Pamala A. PawloskiPark Nicollet Clinic - Saint Louis Park6 years of reported clinical research
Studies Cancer
Studies Relapse
14 reported clinical trials
19 drugs studied
Clinical Trials running at Minnesota Oncology - Burnsville
Lung Cancer
Breast Cancer
Prostate Cancer
Cancer
Colorectal Cancer
Breast cancer
Ovarian Cancer
Pancreatic Cancer
Bladder Cancer
Esophageal cancer
Immunotherapy + Chemotherapy
for Non-Small Cell Lung Cancer
This phase III ALCHEMIST treatment trial tests the addition of pembrolizumab to usual chemotherapy for the treatment of stage IIA, IIB, IIIA or IIIB non-small cell lung cancer that has been removed by surgery. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Chemotherapy drugs, such as cisplatin, pemetrexed, carboplatin, gemcitabine hydrochloride, and paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving pembrolizumab with usual chemotherapy may help increase survival times in patients with stage IIA, IIB, IIIA or IIIB non-small cell lung cancer.
Recruiting2 awards Phase 327 criteria
Osimertinib + Bevacizumab
for Lung Cancer
This phase III trial compares the effect of bevacizumab and osimertinib combination vs. osimertinib alone for the treatment of non-small cell lung cancer that has spread outside of the lungs (stage IIIB-IV) and has a change (mutation) in a gene called EGFR. The EGFR protein is involved in cell signaling pathways that control cell division and survival. Sometimes, mutations in the EGFR gene cause EGFR proteins to be made in higher than normal amounts on some types of cancer cells. This causes cancer cells to divide more rapidly. Osimertinib may stop the growth of tumor cells by blocking EGFR that is needed for cell growth in this type of cancer. Bevacizumab is in a class of medications called antiangiogenic agents. It works by stopping the formation of blood vessels that bring oxygen and nutrients to tumor. This may slow the growth and spread of tumor. Giving osimertinib with bevacizumab may control cancer for longer and help patients live longer as compared to osimertinib alone.
Recruiting2 awards Phase 331 criteria
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Minnesota Oncology - Burnsville?
Minnesota Oncology - Burnsville is a medical facility located in Burnsville, Minnesota. This center is recognized for care of Breast Cancer, Cancer, Lung Cancer, Breast cancer, Non-Small Cell Lung Cancer and other specialties. Minnesota Oncology - Burnsville is involved with conducting 130 clinical trials across 281 conditions. There are 10 research doctors associated with this hospital, such as David M. King, Daniel M. Anderson, Yan Ji, and Pamala A. Pawloski.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.